Meet Your Technology Provider
What Drives Our Work
Mission
Our mission is to address the translatability gap from basic drug development to clinical trials by leveraging cutting-edge transposase technology, our SRG Rat® platform, and cell line development services to reduce timelines and improve clinical results.
Vision
Our vision is to deliver state-of-the-art gene editing technologies that advance discovery research and cell line development, enabling the creation of custom cell lines and genetically modified models that improve bioprocessing and drive superior clinical predictability.
Hera’s Technology Provides Your Research Program With:
Our Story
Born from cutting-edge gene editing technology developed by Transposagen Biopharmaceuticals, Hera forged its own path in 2015 to bring novel models and cell-line engineering expertise to early-stage drug development researchers.
In the following years, we used our proprietary technologies to build the SRG Rat® platform, a double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. In 2017, the SRG Rat® was launched and quickly adopted by major research institutions and industry thanks to its larger size, excellent tumor take-rates, and smooth transition from efficacy to safety studies. To bring this improved model to the global research community, we partner with Charles River for breeding and distribution in 2022.
In 2024, Hera expanded its platform by launching cell line development services for the bioprocessing of therapeutic proteins using a proprietary CHO-K1 host system called CleanCut™ GS CHO.
In 2025, Hera merged with Demeetra, our sister company. This combination enhances the experience of Hera’s customers because we are now fully dedicated to providing the highest quality piggyBac and other gene editing reagents, as well as cell line development services.
